title: It is time to use treponema-specific antibody screening tests for diagnosis of syphilis.
abstract: Assays that detect treponema-specific antibodies, which are either automated or can be done as point-of-care tests, have been developed, some of which are FDA approved. These assays have the advantage of being easily performed and demonstrate high sensitivity, both key features of an infectious disease screening test. As a result, many high-volume clinical laboratories have begun to offer a reverse syphilis testing algorithm where a treponema-specific test is used for screening, followed by a nontreponemal test (i.e., rapid plasma reagin [RPR]) to assess disease activity and treatment status. Concerns about physicians being able to understand and apply this new testing algorithm have been expressed (8). In this point-counterpoint, Michael Loeffelholz of the University of Texas Medical Branch at Galveston explains why his laboratory has adopted this reverse algorithmic approach. Matthew Binnicker of the Mayo Clinic, Rochester, MN, explains why the reverse algorithm may not be suitable for all clinical laboratories and every clinical situation.
authors.affiliation: Department of Pathology University of Texas Medical Branch Galveston, Texas, USA. mjloeffe@utmb.edu
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Loeffelholz
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Binnicker
mesh_terms: D000465:Algorithms; D000907:Antibodies, Bacterial / Q000097:blood*; D019411:Clinical Laboratory Techniques / Q000379:methods*; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008403:Mass Screening / Q000379:methods*; D013587:Syphilis / Q000175:diagnosis*; D014208:Treponema / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial
references.citation: Ann Intern Med. 1991 Jun 15;114(12):1005-9
references.pmid: 2029095
references.citation: J Clin Microbiol. 2012 Jan;50(1):148-50
references.pmid: 22090407
references.citation: J Clin Pathol. 1992 Jan;45(1):37-41
references.pmid: 1740512
references.citation: MMWR Morb Mortal Wkly Rep. 2008 Aug 15;57(32):872-5
references.pmid: 18701877
references.citation: Sex Transm Dis. 2011 Jan;38(1):1-7
references.pmid: 20739911
references.citation: Br J Vener Dis. 1975 Aug;51(4):227-31
references.pmid: 1098730
references.citation: Int J STD AIDS. 2009 May;20(5):300-9
references.pmid: 19386965
references.citation: J Clin Microbiol. 2000 Mar;38(3):1279-82
references.pmid: 10699042
references.citation: Sex Transm Dis. 2011 Mar;38(3):190-6
references.pmid: 20706176
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Feb 11;60(5):133-7
references.pmid: 21307823
references.citation: J Infect Dis. 2011 Nov;204(9):1297-304
references.pmid: 21930610
references.citation: J Clin Microbiol. 1997 May;35(5):1141-3
references.pmid: 9114396
references.citation: Genitourin Med. 1989 Apr;65(2):72-8
references.pmid: 2666302
references.citation: Int J STD AIDS. 2008 Jun;19(6):393-9
references.pmid: 18595877
references.citation: Commun Dis Public Health. 2000 Sep;3(3):158-62
references.pmid: 11014025
references.citation: J Clin Lab Anal. 2009;23(1):1-6
references.pmid: 19140205
references.citation: Clin Diagn Lab Immunol. 2005 Oct;12(10):1231-4
references.pmid: 16210488
references.citation: Clin Vaccine Immunol. 2011 Nov;18(11):2005-6
references.pmid: 21880852
references.citation: J Clin Microbiol. 2011 Apr;49(4):1313-7
references.pmid: 21346050
references.citation: Eur J Clin Microbiol Infect Dis. 2007 Oct;26(10):705-13
references.pmid: 17647033
references.citation: Clin Infect Dis. 2010 Sep 15;51(6):700-8
references.pmid: 20687840
references.citation: J Clin Microbiol. 1982 Apr;15(4):630-4
references.pmid: 7040460
references.citation: Clin Microbiol Rev. 1995 Jan;8(1):1-21
references.pmid: 7704889
references.citation: Clin Vaccine Immunol. 2011 Jun;18(6):1038-40
references.pmid: 21508162